A Garage Sale for MannKind

What do you do when you have more stuff than you have room for? You hold a garage sale. That appears to be the situation that biotech MannKind  (Nasdaq: MNKD  ) finds itself in these days.

Some pharmaceutical companies boast pipelines with dozens of drugs. Pfizer  (NYSE: PFE  ) , for example, has 78 drugs in its pipeline, with 25 of those either in late-stage studies or regulatory review. Of course, Pfizer also sits on more than $25 billion in cash, with $62 billion in revenue over the past year.

To be blunt, MannKind ain't Pfizer. MannKind had the grand sum of 2.12 million in cash, equivalents, and short-term investments on its third-quarter balance sheet (although the company subsequently netted $86 million on a secondary offering). Its revenue over the past 12 months is $35,000. The company is preparing for what it hopes to be the third and final NDA submission for its inhalable insulin Afrezza next year. While MannKind's recent share offering and credit line provide enough funds to move forward, the company will either live or die based on what happens with Afrezza. 

MannKind's garage sale
While MannKind's hopes are pinned on Afrezza, the company does have more products in its pipeline. One is its MKC1106 cancer immunotherapy drug. The drug showed promise in early-stage testing and advanced to a phase 2 study.

However, MannKind doesn't have room from a resource standpoint to handle anything other than Afrezza. The company halted development on most other programs to focus primarily on its inhalable insulin program. That's where the garage sale comes into play.

MannKind announced on Nov. 13 that it inked a deal with privately held Colby Pharmaceutical. Colby will gain exclusive global rights to MKC1106. In return, MannKind will receive an upfront payment and potential milestone payments that could total $140 million. MannKind will also receive tiered royalties if MKC1106 makes its way to market. 

This isn't the first item to be sold from the garage. In April, MannKind announced an agreement to license its Bruton's tyrosine kinase program to Tolero Pharmaceuticals. That arrangement could ultimately generate up to $130 million in upfront and milestone payments. 

The potential exists for more deals. MannKind thinks that its Technosphere technology could be used to more effectively deliver other drugs that currently require injections. 

Good moves
By no means am I disparaging MannKind's actions in comparing the licensing arrangements to a garage sale. On the contrary, I think these are good moves for the company.

Eli Lilly  (NYSE: LLY  ) and Novo Nordisk  (NYSE: NVO  ) both abandoned inhalable insulin products while still in testing because of commercial viability concerns. Pfizer made it to market with Exubera, but it flopped because customers didn't want the product.

Afrezza shows great promise in achieving the success that eluded these earlier products, but MannKind must make it to the finish line to claim that promise. Every dollar counts in enduring the next year or so until the Food and Drug Administration decides on approval for the drug. If a garage sale helps MannKind get there, that sounds good to me.

Still down around 90% from its highs less than a decade ago, there’s been no giant leap for MannKind shareholders. The debate rages over whether its revolutionary inhalable insulin will be a complete flop or a massive blockbuster success. In this brand new premium report on MannKind, we outline every key topic investors have to know with this risky stock. It also comes with a full year of analyst updates to keep you covered as key news develops, so don't miss out -- simply click here now to claim your copy today.


Read/Post Comments (5) | Recommend This Article (8)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 19, 2012, at 5:05 PM, WCoastGuynCA wrote:

    If an investor had to chose one bio-tech stock to buy today and hold for twelve months with a reasonable expectation of a substantial profit I think Mannkind (MNKD) would be the stock to buy with it currently trading under $2.00.

    Bank of America recently placed a "buy" rating on the stock.

    It's quite likely that Afrezza's approval and a subsequent "big pharma" marketing partnership could easily move Mannkind's share price to the $12.00-$15.00 range. Anyone who followed VVUS,ARNA, or DNDN is aware of what can happen to a company's share price during an approval run-up and beyond.

  • Report this Comment On November 19, 2012, at 5:15 PM, WCoastGuynCA wrote:

    Mannkind currently has over $200,000,000 dollars available to it which will fund the company through 2014.

    Please try to be current.

  • Report this Comment On November 19, 2012, at 8:34 PM, rufustherat1 wrote:

    At least get some basic facts right

    "To be blunt, MannKind ain't Pfizer. MannKind has the grand sum of $2.12 million" - In the last month, it raised $92 million in a secondary offering. And it has a $120 million line of credit with its billionaire founder, CEO, and namesake Al Mann. Further extra $90 million could come in if warrants are exercised

    Pretty sloppy of the author not to mention that

  • Report this Comment On November 20, 2012, at 12:53 AM, mbracket123 wrote:

    Hi Keith,

    Please mann-up and respond to your error about current cash amount as the previous respondents have noted.

    Could you explain how you could have missed the shelf-registration, subsequent offering, and abundant follow-up news articles before composing such an article.

    Greatly appreciated.

  • Report this Comment On November 20, 2012, at 10:49 AM, TMFFishBiz wrote:

    WCoastGuynCA, rufustherat1 and mbracket123 are all correct that MannKind did recently raise cash through a share offering that isn't yet reflected in financial statements. The company netted $86 million from this offering. It is also true that MannKind has a credit line that allows the company to borrow additional funds.

    We are updating the article to reflect this. It wasn't my intention to imply that MannKind wouldn't have the financial resources to continue moving forward with Afrezza.

    My main point was that MannKind is doing the right thing, in my opinion, by licensing the other products and focusing on Afrezza. It's not in a financial position to support multiple products like many other companies are. That's not a knock, it's just the way things are. If Afrezza lives up to its potential, we could have a very different story.

    I apologize for any confusion. As always, thanks for reading!

    Keith

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2119013, ~/Articles/ArticleHandler.aspx, 8/30/2014 4:13:29 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement